Millennium Management’s Minerva Neurosciences NERV Stock Holding History

Millennium Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.27M	Buy	708,291 +570,380	+414%	+$3.27M	﹤0.01%	3129
2025 Q4	$554K	Buy	+137,911	New	+$512K	﹤0.01%	4877
2023 Q1	–	Sell	-28,881	Closed	-$46K	–	6682
2022 Q4	$46K	Buy	28,881 +321	+1%	+$1.39K	﹤0.01%	5802
2022 Q3	$264K	Sell	28,560 -51,076	-64%	-$303K	﹤0.01%	5466
2022 Q2	$264K	Sell	79,636 -18,874	-19%	-$77.1K	﹤0.01%	5465
2022 Q1	$654K	Sell	98,510 -1,415	-1%	-$8.68K	﹤0.01%	4903
2021 Q4	$640K	Buy	99,925 +2,497	+3%	+$23.5K	﹤0.01%	4830
2021 Q3	$1.36M	Sell	97,428 -64,378	-40%	-$968K	﹤0.01%	4350
2021 Q2	$3M	Buy	161,806 +90,356	+126%	+$1.94M	﹤0.01%	3437
2021 Q1	$1.67M	Buy	71,450 +20,632	+41%	+$516K	﹤0.01%	3705
2020 Q4	$951K	Buy	50,818 +40,791	+407%	+$1.03M	﹤0.01%	3777
2020 Q3	$255	Buy	10,027 +6,805	+211%	+$184K	﹤0.01%	3941
2020 Q2	$93K	Sell	3,222 -92,221	-97%	-$5.41M	﹤0.01%	3984
2020 Q1	$4.6M	Sell	95,443 -6,734	-7%	-$406K	0.01%	1387
2019 Q4	$5.81M	Buy	102,177 +20,355	+25%	+$898K	0.01%	1806
2019 Q3	$5.07M	Sell	81,822 -16,789	-17%	-$951K	0.01%	1797
2019 Q2	$4.44M	Sell	98,611 -16,705	-14%	-$836K	0.01%	1868
2019 Q1	$7.25M	Sell	115,316 -41,144	-26%	-$2.47M	0.01%	1506
2018 Q4	$8.44M	Buy	156,460 +8,732	+6%	+$639K	0.01%	1231
2018 Q3	$14.8M	Buy	147,728 +32,794	+29%	+$2.46M	0.02%	1032
2018 Q2	$7.59M	Buy	114,934 +3,137	+3%	+$191K	0.01%	1508
2018 Q1	$5.59M	Buy	111,797 +87,152	+354%	+$4.19M	0.01%	1727
2017 Q4	$1.19M	Sell	24,645 -6,483	-21%	-$321K	﹤0.01%	2588
2017 Q3	$1.89M	Buy	31,128 +23,832	+327%	+$1.37M	﹤0.01%	2198
2017 Q2	$517K	Sell	7,296 -2,162	-23%	-$140K	﹤0.01%	2785
2017 Q1	$613K	Sell	9,458 -57,554	-86%	-$4.47M	﹤0.01%	2701
2016 Q4	$6.3M	Sell	67,012 -40,066	-37%	-$4.09M	0.01%	1181
2016 Q3	$12.1M	Buy	107,078 +3,255	+3%	+$316K	0.02%	821
2016 Q2	$8.48M	Buy	103,823 +100,803	+3,338%	+$6.41M	0.02%	952
2016 Q1	$148K	Buy	+3,020	New	+$129K	﹤0.01%	3019
2014 Q4	–	Sell	-1,890	Closed	-$91K	–	4164
2014 Q3	$91K	Buy	+1,890	New	+$100K	﹤0.01%	3563

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Millennium Management's NERV Position: Q1 2026 in Review

Millennium Management increased its Minerva Neurosciences (NERV) stake by 414% in Q1 2026, buying an estimated $3.27M and bringing the position to 708,291 shares worth $4.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

Millennium Management first reported a position in NERV in Q3 2014 and has held it in 31 quarters since. The position peaked at $14.8M in Q3 2018. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Millennium Management held 708,291 shares of Minerva Neurosciences worth $4.27M as of Q1 2026.
Millennium Management bought 570,380 Minerva Neurosciences shares in Q1 2026, an estimated $3.27M.
Minerva Neurosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3129 holding.
Millennium Management first reported a position in Minerva Neurosciences in Q3 2014 and has held it in 31 quarters since.
Millennium Management's Minerva Neurosciences position peaked at $14.8M in Q3 2018.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.